Company overview

We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
Founded in 1999
Valby, Capital Region of Denmark, DNK
2.7K employees (107 in marketing)
92% recommend to a friend
91% positive business outlook

Salaries

Help build salary transparency at Genmab

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

16 open now

Headcount trend

Company growth over the last 12 months

Headcount +16.5% year over year

Funding

Total funding

$11.7B

Last raise

$6B

Post IPO Debt, 4 months ago

Funding history

Nov 2025

Post IPO Debt Genmab · $6B

Sep 2025

Post IPO Debt Genmab · $5.5B

Jul 2010

Post IPO Equity Genmab · $134M

Oct 2009

Post IPO Equity Genmab · $23M

Jun 2000

Venture Round Genmab · $40.5M

Apr 2000

Venture Round Genmab · $4.8M

Audience

Monthly website visitors
114.3K
Month over month+36.9%
Quarter over quarter+50.1%
Top sourceSearch (46.3%)
Ad budget per month$4.1K
Average search rank49.1
Traffic source mix
Search
46.3%
Direct
38.3%
Referral
8.6%
Social
4.9%
Paid referral
1.7%

LinkedIn followers

Follower count and growth

Total followers

151.8K

12-mo growth

+33.6%

Monthly growth

+3.8%

News

Links